bioAffinity Reports Accelerated CyPath® Lung Sales and New Pipeline Progress
BIAF sits 20% above its 52-week low of $0.693 on light trading volume (0.3× avg).
Summary
bioAffinity Technologies released a newsletter detailing significant acceleration in CyPath® Lung sales and new developments in its product pipeline, including a pilot study for asthma/COPD diagnostics and preclinical research for skin cancer therapeutics.
Key Events · Product Development and Regulatory · BIAF
-
Accelerated CyPath® Lung Sales
Unit sales for CyPath® Lung in April increased nearly 300% compared to April 2025, with continued accelerated growth reported in Q2 2026. The number of physician ordering sites grew 69% from Q1 2025 to Q1 2026.
-
New Pipeline Developments
The company initiated a pilot study with Brooke Army Medical Center for asthma and COPD companion diagnostics and reported positive preclinical research findings for topical skin cancer treatments.
-
Philips Partnership Update
The newsletter reiterated the collaboration with Philips and 4DMedical to enhance lung cancer screening programs for U.S. Veterans, with an upcoming webinar scheduled for July 21.
Analysis · BIAF · Industrial Applications And Services
This 8-K, attaching a company newsletter, provides a crucial operational update following the company's recent $3.2 million public offering and prior "going concern" warning. The reported acceleration in CyPath® Lung sales, including a nearly 300% increase in April year-over-year and continued Q2 growth, demonstrates execution and potential for revenue generation. Additionally, new pipeline developments in asthma/COPD diagnostics and topical skin cancer treatments offer future growth avenues, which are vital for a micro-cap company focused on extending its cash runway.
How filings like this one have moved
In the 30 days to Oct 30, 2026, 38.3% of the 891 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BIAF was trading at $0.83 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $5.1M. The 52-week trading range was $0.69 to $13.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.